Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients by Morace, Giulia et al.
RESEARCH ARTICLE Open Access
Antifungal susceptibility of invasive yeast isolates
in Italy: the GISIA3 study in critically ill patients
Giulia Morace
1*, Elisa Borghi
1, Roberta Iatta
2, Gerardino Amato
3, Stefano Andreoni
4, Gioconda Brigante
5,
Claudio Farina
6, Giuliana Lo Cascio
7, Gianluigi Lombardi
8, Ester Manso
9, Michele Mussap
10, Patrizia Pecile
11,
Roberto Rigoli
12, Elisabetta Tangorra
13, Maria Valmarin
14 and Maria Teresa Montagna
2
Abstract
Background: Yeasts are a common cause of invasive fungal infections in critically ill patients. Antifungal
susceptibility testing results of clinically significant fungal strains are of interest to physicians, enabling them to
adopt appropriate strategies for empiric and prophylactic therapies. We investigated the antifungal susceptibility of
yeasts isolated over a 2-year period from hospitalised patients with invasive yeast infections.
Methods: 638 yeasts were isolated from the blood, central venous catheters and sterile fluids of 578 patients on
general and surgical intensive care units and surgical wards. Etest strips and Sensititre panels were used to test the
susceptibility of the isolates to amphotericin B, anidulafungin, caspofungin, fluconazole, itraconazole, posaconazole
and voriconazole in 13 laboratories centres (LC) and two co-ordinating centres (CC). The Clinical and Laboratory
Standards Institute (CLSI) reference broth microdilution method was used at the CCs for comparison.
Results: Etest and Sensititre (LC/CC) MIC90 values were, respectively: amphotericin B 0.5/0.38, 1/1 mg/L;
anidulafungin 2/1.5 and 1/1 mg/L; caspofungin 1/0.75 and 0.5/0.5 mg/L; fluconazole 12/8 and 16/16 mg/L;
itraconazole 1/1.5, 0.5/0.5 mg/L; posaconazole 0.5 mg/L and voriconazole 0.25 mg/L for all. The overall MIC90 values
were influenced by the reduced susceptibility of Candida parapsilosis isolates to echinocandins and a reduced or
lack of susceptibility of Candida glabrata and Candida krusei to azoles, in particular fluconazole and itraconazole.
Comparison of the LC and CC results showed good Essential Agreement (90.3% for Etest and 92.9% for Sensititre),
and even higher Categorical Agreement (93.9% for Etest and 96% for Sensititre); differences were observed
according to the species, method, and antifungal drug. No cross-resistance between echinocandins and triazoles
was detected.
Conclusions: Our data confirm the different antifungal susceptibility patterns among species, and highlight the
need to perform antifungal susceptibility testing of clinically relevant yeasts. With the exception of a few species (e.
g. C. glabrata for azoles and C. parapsilosis for echinocandins), the findings of our study suggest that two of the
most widely used commercial methods (Etest and Sensititre) provide valid and reproducible results.
Background
Severe yeast infections, especially candidaemia, represent
a significant health problem in patients at high risk of
infection, leading to increased morbidity and mortality,
greater healthcare costs and increased duration of hospi-
talisation [1,2]. Although Candida albicans is the most
common species associated with candidaemia, the
incidence of non-albicans Candida spp. is increasing.
According to a recent report from North America, there
has been a change in the epidemiology of candidaemia
in the US, with C. albicans responsible for only 45.6% of
cases and Candida glabrata (26%) now the second most
common cause of yeast infection [3], while in a previous
report C. albicans was responsible for 58% of cases and
C. glabrata for 20% of cases [4]. In Europe, C. albicans
is still responsible for the majority (56.4%) of yeast
infections; however, this figure is subject to considerable
variation (42.7-67%) and is dependent on patient co-
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any medium, provided the original work is properly cited.morbidities and risk factors [5]. In Italy, Candida para-
psilosis is the second most common causative species,
although it is less virulent than C. glabrata and Candida
tropicalis [6-8]. Invasive infections caused by non albi-
cans Candida spp. are more difficult to treat because of
their innate or easily-acquired resistance to antifungal
agents; therefore, the selection of drug treatment should
be based on species-level identification. Furthermore,
timely administration of antifungal drugs is mandatory
because appropriate therapy and early treatment are
associated with improved outcome in patients with fun-
gal bloodstream infections [9].
The recent introduction of antifungal drugs with dif-
ferent mechanisms of action such as the echinocandins
(e.g. caspofungin, micafungin and anidulafungin) and
second-generation triazoles, together with the improved
performance of antifungal susceptibility testing (AFST)
methods justifies the greater use of AFST in clinical
practice. Although AFST results should be interpreted
with caution, particularly when commercial methods are
used, they can serve as a useful guide in the selection of
antifungal therapy. Clinical correlation between AFST
results and patient outcome is very difficult to establish;
however, it is widely accepted that a patient infected
with a fungus with a high minimum inhibitory concen-
tration (MIC) for a particular antifungal agent is unlikely
to exhibit a good response to the drug [10]. Moreover
national and local data on antifungal susceptibilities of
clinically significant fungal strains are of interest to phy-
sicians, enabling them to adopt appropriate strategies
for empiric and prophylactic therapies.
The present 2-year laboratory-based study was con-
ducted to investigate the antifungal susceptibility of
yeast species isolated from critically ill patients with
invasive yeast infections in Italy in 13 laboratories cen-
tres (LC) and two co-ordinating centres (CC). The pri-
mary aim of the study was to characterize the freshly
isolated yeast strains in terms of their in vitro suscept-
ibility to systemic antifungal drugs that were available in
Italy at the time of the study. As secondary objectives
we evaluated the inter- and intra-laboratory reproduci-
bility of two commercially available methods (Etest and
Sensititre) for testing the susceptibility of yeasts to anti-
fungal drugs and their level of agreement with the Clini-
cal and Laboratory Standards Institute (CLSI) M27-A2
reference broth microdilution method [11].
Methods
Clinical isolates
All yeast isolates, recovered from the blood and sterile
specimens of critically ill patients on general and surgi-
cal intensive care units and surgical wards over a period
of 2 years (January 2007 to December 2008), were
included in the study and analysed at 13 Italian local
microbiology centres (LC). Isolates of the same species
originating from the same patient were included only if
they had been isolated from different specimens (i.e.
b l o o da n ds p i n a lf l u i d )o rf r o mt h es a m es p e c i m e nb u t
at least 15 days apart. For this study, we did not use any
additional data or samples other than those obtained
during routine activity of our laboratories. Therefore,
neither ethical approval nor patient consensus was con-
sidered necessary. The isolates were identified using
standard procedures, (i.e. morphology on cornmeal agar
plates, germ-tube production in serum, and biochemical
analysis using the Vitek system Yeast Biochemical cards,
API 20CAUX test, or ATB 32C panels [Bio-Merieux,
Rome, Italy]) [12]. Prior to susceptibility testing, each
isolate was sub-cultured on Sabouraud dextrose agar to
ensure viability, purity, and optimal growth characteris-
tics. After testing, each isolate was frozen at -80°C.
Tested isolates were periodically transferred to one of
two coordinating centres (CC) for the study, where they
were re-tested and stored under appropriate conditions
until the study was complete and the study analysis had
been performed. In addition, the quality control isolates
Candida krusei ATCC 6258 and C. parapsilosis ATCC
22019 listed in the CLSI M27-A2 document were tested
[11].
Drugs and reference method panels
The isolated yeast strains were tested for their in vitro
susceptibility to amphotericin B, caspofungin, flucona-
zole, itraconazole, voriconazole, anidulafungin and posa-
conazole. Micafungin was not included because it was
not available from the manufacturer at the time the
study was conducted. Fluconazole, voriconazole and ani-
dulafungin (Pfizer Pharmaceuticals, Groton, CT, USA),
caspofungin (Merck & Co, Inc, Whitehouse Station, NJ,
USA), and posaconazole (Schering Plough Corporation,
Kenilworth, NJ, USA) were obtained as standard pow-
ders from their manufacturers; amphotericin B and itra-
conazole were purchased from Sigma-Aldrich, Milan,
Italy. Caspofungin and fluconazole were dissolved in
sterile water whereas all other drugs were dissolved in
dimethyl sulfoxide. The broth microdilution panels for
the reference method were prepared at each CC in
accordance with the CLSI M27-A2 document [11] and
literature data for the two echinocandins [13], stored at
-80°C and used for testing within 6 months of the pre-
paration date. With the exception of fluconazole (con-
centration range 0.125-128 mg/L), the antifungal drug
concentrations ranged from 0.008 to 16 mg/L.
Inoculum suspension
After overnight growth on Sabouraud dextrose agar at
35 °C, each isolate was suspended in 5 ml of sterile dis-
tilled water and thoroughly vortexed to achieve a
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530 nm) was adjusted to a McFarland standard of 0.5
with sterile distilled water. This suspension (approxi-
mately 1-5 x 10
6 CFU/mL) was used for Etest suscept-
ibility testing (AB BIODISK, Solna, Sweden, now Bio-
Merieux). For assays performed using broth microdilu-
tion methods, i.e. Sensititre (Trek Diagnostic Systems
Ltd, East Grinstead, Sussex, UK) and the CLSI M27-A2
reference method, appropriate dilutions were prepared
according to manufacturer recommendations or the
standardized protocol (CLSI M27-A2) as appropriate.
Susceptibility testing
All LCs and CCs performed susceptibility testing of each
isolate using the Sensititre and Etest methods. In addi-
tion, the two CCs evaluated the antifungal susceptibility
testing of the yeast isolates in comparison with the
reference CLSI M27-A2 method.
Etest assays were performed using RPMI agar plates
(Biolife, Milan, Italy), as recommended by the manufac-
turer. The plates were incubated at 35°C and read after
24 hours; if no growth was detected the plates were
incubated for a further 24 hours. The drug concentra-
tion shown on the Etest strip at the outer border of the
elliptical inhibition halo was recorded as the MIC. For
triazoles, the growth of microcolonies within this inhibi-
tion zone was disregarded.
Panels for the Sensititre test were provided by Trek
Diagnostic Systems. Readings were taken after 24 hours
and if no growth was detected the panels were incu-
bated for a further 24 hours. MICs were determined by
visual inspection of the plates; the concentration of the
first well that remained blue (absence of growth) was
recorded as the MIC. For azoles, the bottom of each
plate was visually inspected to avoid erroneous MIC
readings caused by the trailing effect.
For the reference CLSI method, a visual reading was
made after 24 hours of incubation, and the lowest con-
centration that produced a prominent decrease in tur-
bidity ( ≥ 50%) relative to that of the drug-free control
well was recorded as MIC. The MIC for amphotericin B
was defined as the lowest concentration at which no
visible growth was detected. After an additional incuba-
tion for 24 hours, the panels were analyzed spectropho-
tometrically (after shaking). For azoles and amphotericin
B, the spectrophotometric reading (48 h) has been pre-
f e r r e dt ot h er e c o m m e n d e dv i s u a lo n et oa v o i db i a s
related to the reader’s expertise and used for the analysis
[13].
Data recording
Complete data (MIC values, date of the test, isolate
number, related identifying number of the two quality
control isolates tested in the same session) for each
yeast isolate tested were recorded on an electronic data
report form (E-DRF) by the investigator of each LC.
The E-DRF was automatically checked by an electronic
validation programme to verify the consistency of data.
If the E-DRF passed this check, it was automatically
saved, printed, and sent to the data management unit;
otherwise, the user was prompted to add missing data.
The printed copy of the E-DRF was signed by the inves-
tigator and filed on site. The same electronic and auto-
mated procedures were adopted for the CC results.
After registration of the CC results, the CCs received a
copy of the E-DRF containing the LC results where the
yeast species had been isolated and tested.
Analysis of results
The LC and CC MIC results were compared. For com-
parative purposes, the Etest MICs were adjusted to the
nearest CLSI concentrations [14,15]. The MIC values
were considered to be in essential agreement (EA)
between two methods or two different tests when they
were within 2 dilutions. Categorical agreement (CA) was
assigned to Candida spp. results obtained by the two CC
using the CLSI M27-A2 reference method and the two
commercial methods that fell within the same interpre-
tive categories (susceptible [S], non-susceptible [NS],
susceptible dose-dependent [SDD] or resistant [R])
according to the following established CLSI MIC break-
points for: fluconazole, S ≤8 mg/L, SDD 16-32 mg/L, R
≥64 mg/L; itraconazole S ≤0.125 mg/L, SDD 0.25-0.5
mg/L, R ≥1 mg/L; voriconazole S ≤1m g / L ,S D D2m g /
L, R ≥4 mg/L [16]. The proposed clinical MIC break-
points for anidulafungin and caspofungin used were S
≤2 mg/L, NS >2 mg/L [17]. Interpretive criteria for
amphotericin B and posaconazole have not been estab-
lished; instead, isolates inhibited by amphotericin B at
concentrations ≤1 mg/L were considered susceptible
and voriconazole breakpoints were applied to the posa-
conazole MIC values [18]. Discrepancies were consid-
ered “major” if an isolate classified as S by the reference
method was classified as R by the commercial method
and “very major” if an isolate classified as R by the refer-
ence method was classified as S by the commercial
method. A minor error was recorded in the case of S vs
SDD, R vs SDD, SDD vs S, or SDD vs R for the azoles.
For echinocandins, categorical errors were considered
“very major” when CLSI MIC indicated NS while Etest
categorized the same isolate as S, and “major” when the
Etest MIC indicated NS and CLSI S.
Results
A total of 638 yeast isolates were collected from 578
patients during the study period. C. albicans (51.3%)
was the most common species. C. parapsilosis (22.6%),
C. glabrata (12.1%), C. tropicalis (6%), and C. krusei
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isolates tested. Non-albicans Candida represented 46.8%
of the isolated species, including 7 C. lusitaniae,7C.
guilliermondii,4C. famata,3C. lipolytica,2C. sake
and 2 C. utilis. The remaining 1.9% belonged to other
genera (10 Cryptococcus neoformans, and 1 each of Geo-
trichum capitatum and Saccharomyces cerevisiae). C.
parapsilosis was more common in Southern and Central
Italy than in Northern Italy (25.7% vs 19.9%), while the
opposite was true for C. glabrata (7.5% vs 15.9%). Only
the latter was statistically significant (p <0.001). Each of
the 13 participating LC provided approximately 50
isolates.
The majority of the isolates were susceptible to all
the antifungal drugs tested (Table 1). The overall
MIC90 values as well as percentage of resistant isolates
were influenced by the reduced susceptibility of Can-
dida parapsilosis complex isolates to echinocandins
and a reduced or lack of susceptibility of Candida
glabrata and Candida krusei to azoles, in particular to
fluconazole and itraconazole. For each drug, similar
MIC90 values were generally obtained using Etest and
Sensititre. The echinocandins were very active against
C. albicans, C. glabrata and C. krusei isolates, although
MIC90 values for anidulafungin were lower than those
of caspofungin against the same species. High MIC
values for both the echinocandins tested were deter-
mined for C. guilliermondii, C. parapsilosis complex,
Cryptococcus neoformans and Geotrichum capitatum.
With the exception of C. glabrata susceptibility to the
azoles (the majority of MIC values were in the SDD or
R category) and C. krusei susceptibility to fluconazole
(MIC90 values were in the R category), all yeasts
showed good susceptibility patterns to the azoles and
amphotericin B. Overall, there was excellent categorical
agreement between the reference method and the two
commercial methods for all thea n t i f u n g a ld r u g st e s t e d
except for itraconazole. The CA percentage for itraco-
nazole was very low for both the Etest and Sensititre
methods; the majority of discrepancies were minor
errors and were probably related to small differences
in the MIC values for the itraconazole breakpoint (S
≤0.125 mg/L; SDD 0.25-0.5 mg/L; R ≥1m g / L ) .T h e
triazoles, fluconazole and posaconazole, exhibited poor
agreement for C. glabrata with low CA percentage
values (Etest: 44.2% and 51.9%, respectively; Sensititre:
40.3% and 68.8%, respectively), but these low CA
values were predominantly associated with minor
errors. The CA percentage for fluconazole was also
low for C. krusei (Etest: 46.7%; Sensititre: 33.3%), in
Table 1 In vitro antifungal susceptibilities of 638 clinical yeast isolates determined by CLSI M27-A2, Etest and
Sensititre
Drug Method MIC values % of R strains CA% % of isolates with discrepant results
Ranges 50% 90% Minor Major Very major
CLSI 0.12-2 0.5 1 2.6
Amphotericin B Etest 0.032-8 0.19 0.38 0.2 97.5 - - 2.5
Sensititre 0.03-2 0.5 1 0.4 97.3 - 0.2 2.5
CLSI <0.008-≥16 0.12 16 3.6
Anidulafungin Etest ≤0.002-≥32 0.008 1.5 3.8 94.7 - 2.1 3.2
Sensititre ≤0.008-≥16 0.06 1 1.7 96.4 - - 3.6
CLSI 0.016-≥16 1 2 6.7
Caspofungin Etest 0.012-≥32 0.19 0.75 2.2 95.0 - 0.2 4.8
Sensititre 0.015-≥16 0.12 0.5 2.2 95.3 - - 4.7
CLSI ≤0.12-128 0.5 16 3.3
Fluconazole Etest 0.032-≥256 0.38 8 2.2 91.1 7.7 0.2 1
Sensititre ≤0.12-≥256 0.5 16 2.7 89.8 0.2 0.2 9.8
Itraconazole CLSI 0.008-≥16 0.25 1 7.8
Etest 0.004-≥32 0.064 1.5 8.9 47.7 49.2 - 3.1
Sensititre ≤0.008-≥8 0.03 1 5.9 46.8 59.2 - 4.0
Posaconazole CLSI ≤0.008-≥8 0.12 1 6.5
Etest 0.003-≥32 0.064 0.5 10.6 93.4 4.8 1.6 0.2
Sensititre ≤0.008-≥8 0.03 1 2.3 96.0 3.5 - 0.5
Voriconazole CLSI ≤0.008-8 0.016 0.25 1.9
Etest ≤0.002-≥32 0.023 0.25 1.4 98.8 0.9 - 0.3
Sensititre ≤0.008-8 0.008 0.25 1.1 98.3 1.0 0.2 0.5
* Categorical Agreement (MIC values that fell within the same interpretive categories)
Morace et al. BMC Infectious Diseases 2011, 11:130
http://www.biomedcentral.com/1471-2334/11/130
Page 4 of 9this case a high number of very major errors occurred
with Sensititre method.
Comparison of the LC and CC results showed good
EA (90.3% for Etest and 92.9% for Sensititre), and even
higher CA (93.9% for Etest and 96% for Sensititre); dif-
ferences were observed according to the species,
method, and antifungal drug (Table 2). The overall EA
for both echinocandins, anidulafungin and caspofungin,
w a sh i g hw i t hb o t hm e t h o d s ,a l t h o u g has l i g h t l yb e t t e r
agreement was observed for the Sensititre results. How-
ever, this difference was not evident for the CA,
although differences were observed among the single
species. As expected, C. parapsilosis isolates were gener-
ally associated with high echinocandin MIC values, with
several isolates above the CLSI breakpoint [17]; this was
more evident for the Etest than for the Sensititre results.
In general, EA percentage for the azoles was lower with
the Etest than with the Sensititre method. This con-
firmed in part the bias associated with subjective reading
of the Etest results, which for some species (e.g. C. albi-
cans and C. tropicalis) is complicated by the presence of
a double halo or lawn of microcolonies within the dis-
cernible ellipse (Figure 1). Itraconazole showed a very
low agreement between LC and CC results with both
methods, in particular for C. glabrata, C. tropicalis and
C.krusei isolates. C. glabrata was the most problematic
species for the azoles; EA was <70% for itraconazole and
posaconazole using the Etest, and the CA percentage
was very low for fluconazole, itraconazole, and posaco-
nazole with both methods (Etest 64.9%, 80.3%, 57.1%,
respectively; Sensititre 58.4%, 66.2%, 77.9%, respectively).
Discussion
The regional variation in the distribution of various
Candida species observed in this study, in particular dif-
ferences in the occurrence of C. glabrata and C. para-
psilosis in northern versus central/southern Italy, may
be attributable to differences relating to climate, the
management of vascular catheters, and the empirical
and prophylactic use of antifungal drugs [7,8].
Our data on antifungal susceptibility suggest that anti-
fungal resistance is low among yeasts isolated from criti-
cally ill patients with invasive infections in Italy. These
results agree with those reported in other Italian publi-
cations, although the studies were conducted on a regio-
nal rather than a national basis [2,19-21]. Furthermore,
our findings highlight the importance of adopting cur-
rent clinical practice guidelines for the management of
invasive yeast infections, particularly candidiasis; these
include European Guidelines for the Management of
Bacterial and Fungal Infections developed by the Eur-
opean Conference on Infections in Leukaemia (ECIL)
[22] and by the Infectious Diseases Society of America
(IDSA) [2].
Resistance to the recently introduced echinocandins
was reported very rarely in our study; only C. neofor-
mans isolates were resistant to both echinocandins, and
the single strain of Geotrichum capitatum showed high
MIC values for both anidulafungin (8 mg/mL) and cas-
pofungin (≥16 mg/L). Some isolates of the C. parapsilo-
sis complex and C. guilliermondii demonstrated a
decreased susceptibility to these drugs, particularly ani-
dulafungin which had Etest MIC values that were higher
than the proposed breakpoint [17]. Further support for
these findings was provided by our comparison of the C.
parapsilosis complex Etest results with those of the
reference method at the CCs which revealed a higher
percentage CA between the reference and Sensititre
methods than between the reference and Etest methods.
Although we detected a lower percentage of very major
(6.2% of false susceptibility) errors compared with the
14% detected by Espinel-Ingroff and coworkers [23], this
observation agrees with their data and corroborates
their conclusion that the Etest is not suitable for testing
the susceptibility of anidulafungin against C. parapsilosis
complex [23].
The majority of our isolates were susceptible in vitro
to amphotericin B and the triazoles, although differences
were observed across species. As expected, C. krusei
demonstrated innate resistance to fluconazole but was
susceptible to posaconazole and voriconazole with MIC
values of 0.5 mg/L for 100% of the isolates tested. The
majority of C. glabrata isolates were not susceptible
(SDD or R category) to triazoles, although differences
were observed for individual triazoles which were prob-
ably related to the different efflux pumps involved in the
development of C. glabrata a z o l er e s i s t a n c e[ 2 4 ] .V o r i -
conazole was the most active azole compound against
C. glabrata with a few isolates exhibiting resistance; this
is in contrast to other reports suggesting that isolates
classified as fluconazole resistant are also resistant to
voriconazole [25]. One major problem we encountered
with C. glabrata was the low rate of agreement between
the two commercial susceptibility test methods and the
reference method, especially for fluconazole and posaco-
nazole. However, this is in agreement with earlier stu-
dies that we have conducted comparing commercial
methods with the CLSI reference method [26,27]. The
poor performance of itraconazole could be attributable
to the small differences in MIC values for the itracona-
zole breakpoint.
Conclusions
Our study demonstrates that clinical yeasts, isolated
from blood and sterile specimens, are generally suscepti-
ble to currently available antifungal drugs indicated for
the treatment of invasive yeast infections in Italy. How-
ever, identification of the yeast species and strain
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species determined by Etest and Sensititre
Drug Species (No of isolates) Centre Etest MIC mg/L °Agreement % Sensititre MIC mg/L °Agreement %
Range 50% 90% EA CA Range 50% 90% EA CA
All isolates (638) LC ≤0.002-1.5 0.19 0.5 93.1 99.4 0.015-2 0.5 1 89.9 98.6
CC 0.032-8 0.19 0.38 0.03-2 0.5 1
Candida albicans (327) LC 0.002-1 0.19 0.25 96.3 100 0.015-1 0.5 1 91.1 99.4
CC 0.032-1 0.19 0.25 0.06-1 0.5 0.5
Candida parapsilosis (144) LC 0.004-1.5 0.125 0.5 85.4 99.3 0.015-2 0.5 1 89.6 98.6
Amphotericin B CC 0.032-0.75 0.19 0.25 0.03-1 0.5 0.5
Candida glabrata (77) LC 0.002-1.5 0.25 0.75 97.4 98.7 0.015-2 0.5 1 87 98.7
CC 0.047-1 0.25 0.5 0.06-1 0.5 1
Candida tropicalis (38) LC 0.032-1.5 0.25 0.5 86.8 97.4 0.06-2 0.5 2 97.7 89.5
CC 0.047-0.75 0.25 0.5 0.12-1 0.5 1
Candida krusei (15) LC 0.064-0.5 0.5 0.5 93.3 100 0.25-1 0.5 1 100 93.2
CC 0.25-1 0.5 1 0.5-2 1 1
All isolates (638) LC ≤0.002-≥32 0.008 2 89.6 93 ≤0.008-≥16 0.06 1 92.5 99.7
CC ≤0.002-≥32 0.008 1.5 ≤0.008-≥16 0.06 1
Candida albicans (327) LC ≤0.002-4 0.003 0.006 89.7 99 ≤0.008-1 0.03 0.06 89.6 100
CC ≤0.002-3 0.003 0.006 ≤0.008-2 0.03 0.06
Anidulafungin Candida parapsilosis (144) LC 0.004-≥32 1.5 4 89.2 74.1 0.03-4 1 2 97.9 98.6
CC ≤0.002-≥32 1 2 ≤0.008-2 1 2
Candida glabrata (77) LC 0.003-2 0.012 0.032 92.0 100 ≤0.008-2 0.03 0.12 94.8 100
CC 0.004-2 0.012 0.023 ≤0.015-2 0.06 0.12
Candida tropicalis (38) LC ≤0.002-0.064 0.016 0.032 84.2 100 ≤0.008-1 0.06 0.25 89.5 100
CC 0.006-1.5 0.016 0.125 0.03-2 0.06 0.25
Candida krusei (15) LC 0.012-0.047 0.023 0.047 100 100 0.015-0.12 0.06 0.12 100 100
CC 0.012-0.047 0.023 0.047 0.06-0.12 0.06 0.12
All isolates (638) LC ≤0.002-≥32 0.19 1 94.5 98.9 ≤0.008-≥16 0.12 0.5 96.7 99.8
CC 0.012-≥32 0.19 0.75 0.015-≥16 0.12 0.5
Candida albicans (327) LC ≤0.002-1 0.125 0.25 94.2 100 0.008-0.5 0.06 0.12 97.9 100
CC 0.012-1.5 0.094 0.19 0.015-1 0.06 0.12
Candida parapsilosis (144) LC 0.032-3 0.75 2 92.3 95.8 0.03-8 0.5 1 95.8 99.3
Caspofungin CC 0.094-3 0.5 1 0.06-2 0.5 1
Candida glabrata (77) LC 0.047-2 0.25 0.38 98.7 100 0.015-≥16 0.12 0.25 97.4 100
CC 0.125-1 0.19 0.25 0.03-≥16 0.12 0.25
Candida tropicalis (38) LC 0.016-0.38 0.19 0.25 94.7 100 0.03-0.5 0.06 0.25 92.1 100
CC 0.064-2 0.19 0.5 0.03-0.5 0.06 0.25
Candida krusei (15) LC 0.38-1 0.75 1 100 100 0.12-1 0.5 0.5 100 100
CC 0.38-1.5 0.5 1 0.12-0.5 0.5 0.5
All isolates (638) LC 0.023-≥256 0.38 12 92.2 93.2 ≤0.12-≥256 0.5 16 94.3 92.8
CC 0.032-≥256 0.38 8 ≤0.12-≥256 0.5 16
Candida albicans (327) LC 0.023-≥256 0.25 0.75 92.0 99.1 ≤0.12-≥256 0.25 0.5 94.8 99.1
CC 0.047-32 0.25 0.75 ≤0.12-32 0.25 0.5
Candida parapsilosis (144) LC 0.32-≥256 0.5 2 95.8 97.2 ≤0.12-128 1 4 97.2 96.7
Fluconazole CC 0.125-32 0.5 1.5 ≤0.12-64 1 4
Candida glabrata (77) LC 0.38-≥256 12 ≥256 84.4 64.9 0.5-≥256 16 64 90.9 58.4
CC 0.125-≥256 8 48 0.5-≥256 16 64
Candida tropicalis (38) LC 0.125-16 0.5 2 92.1 100 0.25-≥256 1 4 84.2 92.1
CC 0.032-32 0.5 2 0.25-16 1 4
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cally relevant yeasts is essential to achieve optimal clini-
cal outcome. Selection of the most appropriate method
for susceptibility testing can be problematic as the low
percentages of CA and EA Etest demonstrated for
some Candida species. However, with the exception of
these few species (e.g. C. glabrata for azoles and C.
parapsilosis for echinocandins), the findings of our
study suggest that two of the most widely used commer-
cial methods (Etest and Sensititre) provide valid and
reproducible results as demonstrated by the blind sus-
ceptibility re-testing of all yeast isolates at the study
CCs. Caution should be adopted when elevated MIC
values are determined by these commercial methods
Table 2 Comparison between LC* and CC* in vitro antifungal susceptibilities of the most representative Candida spe-
cies determined by Etest and Sensititre (Continued)
Candida krusei (15) LC 12-≥256 48 ≥256 86.7 46.7 8-64 32 64 100 86.7
CC 16-128 32 64 32-64 32 64
All isolates (638) LC ≤0.002-≥32 0.064 1 81.3 79.4 ≤0.008-≥16 0.06 0.5 92.5 84.4
CC 0.004-≥32 0.064 1.5 ≤0.008-≥16 0.06 0.5
Candida albicans (327) LC 0.002-≥32 0.047 0.25 84.1 80.4 ≤0.008-≥16 0.03 0.12 92.7 94.1
CC 0.004-1 0.064 0.25 ≤0.008-0.25 0.06 0.12
Candida parapsilosis (144) LC ≤0.002-1 0.032 0.25 87.5 84.7 ≤0.008-0.5 0.12 0.12 94.4 82.7
Itraconazole CC 0.008-3 0.032 0.38 ≤0.008-1 0.12 0.25
Candida glabrata (77) LC ≤0.002-≥32 1.5 ≥32 61.8 80.3 0.03-≥16 0.5 ≥16 89.6 66.2
CC 0.004-≥32 2 ≥32 0.06-≥16 0.5 2
Candida tropicalis (38) LC 0.012-16 0.094 0.38 68.4 55.3 0.03-≥16 0.12 0.5 86.8 36.8
CC 0.016-3 0.125 1 0.06-1 0.25 0.5
Candida krusei (15) LC 0.125-32 1 2 86.7 73.3 0.12-0.5 0.25 0.5 100 73.3
CC 0.5-2 1 2 0.12-0.5 0.25 0.5
All isolates (638) LC ≤0.002-≥32 0.064 0.5 92.8 94.2 ≤0.008-≥8 0.03 0.5 91.8 96.1
CC 0.003-≥32 0.064 0.5 ≤0.008-≥8 0.03 1
Candida albicans (327) LC ≤0.002-≥32 0.047 0.094 95.7 99.7 ≤0.008-≥8 0.015 0.03 90.8 98.8
CC 0.003-0.25 0.047 0.094 ≤0.008-0.5 0.015 0.03
Candida parapsilosis (144) LC 0.003-0.25 0.064 0.125 98.6 99.3 ≤0.008-4 0.03 0.12 95.1 99.3
Posaconazole CC 0.012-4 0.047 0.125 ≤0.008-1 0.06 0.12
Candida glabrata (77) LC 0.003-≥32 1 ≥32 66.2 57.1 ≤0.008-≥8 0.5 ≥8 90.9 77.9
CC 0.012-≥32 1 24 0.015-≥81 ≥8
Candida tropicalis (38) LC 0.016-1.5 0.094 0.19 94.7 97.4 0.015-≥8 0.12 1 84.2 92.1
CC 0.016-2 0.094 0.25 0.015-1 0.12 1
Candida krusei (15) LC 0.094-1 0.25 0.5 93.3 100 0.12-0.5 0.25 0.5 100 100
CC 0.19-0.5 0.25 0.5 0.12-0.5 0.25 0.5
All isolates (638) LC ≤0.002-≥32 0.016 0.25 90.3 98.9 ≤0.008-≥16 0.008 0.25 91.5 99.0
CC ≤0.002-≥32 0.023 0.25 ≤0.008-8 0.008 0.25
Candida albicans (327) LC ≤0.002-≥32 0.012 0.032 86.2 99.4 ≤0.008-≥16 ≤0.008 0.015 92.7 99.4
CC ≤0.002-0.25 0.016 0.047 ≤0.008-0.25 ≤0.008 ≤0.008
Candida parapsilosis (144) LC ≤0.002-1 0.016 0.094 91.7 100 ≤0.008-1 0.015 0.12 90.3 100
Voriconazole CC ≤0.002-1 0.016 0.094 ≤0.008-1 0.015 0.06
Candida glabrata (77) LC 0.004-≥32 0.25 1.5 85.7 94.8 ≤0.008-≥16 0.25 1 89.6 89.6
CC 0.006-≥32 0.25 1.5 ≤0.008-8 0.25 1
Candida tropicalis (38) LC 0.016-0.5 0.047 0.125 86.8 100 ≤0.008-16 0.06 1 86.8 94.7
CC 0.012-1 0.064 0.25 0.015-1 0.06 0.25
Candida krusei (15) LC 0.094-0.75 0.25 0.5 100 100 0.06-0.5 0.25 0.5 100 100
CC 0.19-0.75 0.38 0.5 0.12-0.5 0.25 0.5
* LC = Laboratory Centre, CC = Coordinating Centre
° EA = Essential Agreement (MIC values within 2 dilutions), CA = Categorical Agreement (MIC values that fell within the same interpretive categories),
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Page 7 of 9among isolates of Candida species generally susceptible
to a given antifungal drug; the possible resistance should
be confirmed by reference methods.
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